AEHR TEST SYSTEMS — Key Metrics
3 years of history · ending 2025-05-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$4
Free Cash Flow Per Share
$-0
Cash Per Share
$1
Revenue Per Share
$2
OCF Per Share
$-0
Return on Equity
-3.3%
Return on Assets
-2.8%
Return on Invested Capital
-3.8%
Debt to Equity
—
Current Ratio
5.68
Quick Ratio
2.99
Asset Turnover
0.43
Days Sales Outstanding
87.84
Days Payables Outstanding
70.09
Days Inventory On Hand
437.53
Cash Conversion Cycle
455.28
R&D / Revenue
17.7%
SBC / Revenue
8.8%
Capex / Revenue
8.5%
Working Capital
$73M
Net Current Asset Value
$63M
Invested Capital
$123M
OCF / Net Income
1.89
FCF / Net Income
3.17
Accruals Ratio (Sloan)
2.4%
Net Debt
$-25M
Net Debt / EBITDA
7.29
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-1.48
Tangible Common Equity
$101M
TCE / Total Assets
68.3%
Goodwill / Total Assets
7.2%
NOPAT
$-4M
Cash ROIC
-10.6%
WC / Revenue
124.0%
Capex / D&A
2.16
Reinvestment Rate
-242.3%
Asset Growth vs Revenue Growth
27.1%
Revenue 5Y CAGR
21.5%
EPS 5Y CAGR
94.1%
EBITDA 5Y CAGR
59.7%
Book Value 5Y CAGR
54.3%
Stock Price (FY-end)
$10
Market Cap
$282M
P/E Ratio
10.28
P/S Ratio
4.79
P/B Ratio
2.30
P/TB Ratio
2.78
P/OCF Ratio
194.13
P/FCF Ratio
338.52
Enterprise Value
$258M
EV / EBITDA
27.18
EV / Sales
4.37
EV / FCF
289.70
FCF Yield
-4.4%
Shareholder Yield
-1.8%
R&D Yield
3.7%
Capex Yield
1.8%
Operating Leverage
-12.74
Graham Number
$10
Shares Variation (YoY)
-0.1%
Beta (5Y)
1.93
Cost of Equity
14.2%
Cost of Debt (after tax)
—
WACC
—
ROIC - WACC Spread
—
52W High
$21
52W Low
$7
Trailing Return 1Y
-17.5%
Trailing Return 5Y
471.3%
F-Score (Piotroski)
1.00
Z-Score (Altman)
7.25
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
AEHR TEST SYSTEMS — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.40% | 0.60% | 0.10% | 0.00% | -51.10% | 0.10% |
| Foreign Rate Differential | -21.50% | 9.80% | 0.30% | 0.70% | 0.20% | 0.10% |
| Other Adjustments | -2.50% | -0.40% | 0.40% | -0.60% | -0.30% | -0.70% |
| R&D Tax Credits | 0.00% | 4.00% | -1.30% | -2.30% | — | — |
| SBC (Nondeductible) | -4.00% | -4.70% | -11.00% | -9.10% | -8.40% | -10.30% |
| Valuation Allowance Change | 4.30% | -32.10% | -4.70% | -9.30% | -126.00% | 0.00% |
| Tax Law Change | 0.00% | 0.00% | -3.70% | 0.00% | 0.00% | — |
| Effective Tax Rate | -1.30% | 8.00% | 1.10% | 0.40% | -1.66% | 8.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$36.0K | −$177.0K | $91.0K | $60.0K | −$20.7M | −$381.0K |
| Income Taxes Paid (Cash) | $42.0K | $15.0K | $4.0K | $21.0K | $90.0K | $100.0K |
AEHR TEST SYSTEMS — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.